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Abstract The important role of tumor-specific cytotoxic
CD8? T cells is well defined in the immune control of the
tumors, but the role of effector CD4? T cells is poorly
understood. In the current research, we have used a murine
retrovirus-induced tumor cell line of C57BL/6 mouse ori-
gin, namely FBL-3 cells, as a model to study basic
mechanisms of immunological control and escape during
tumor formation. This study shows that tumor-specific
CD4? T cells are able to protect against virus-induced
tumor cells. We show here that there is an expansion of
tumor-specific CD4? T cells producing cytokines and
cytotoxic molecule granzyme B (GzmB) in the early phase
of tumor growth. Importantly, we demonstrate that in vivo
depletion of regulatory T cells (Tregs) and CD8? T cells in
FBL-3-bearing DEREG transgenic mice augments IL-2
and GzmB production by CD4? T cells and increases
FV-specific CD4? T-cell effector and cytotoxic responses
leading to the complete tumor regression. Therefore, the
capacity to reject tumor acquired by tumor-reactive CD4?
T cells largely depends on the direct suppressive activity of
Tregs. We suggest that a cytotoxic CD4? T-cell immune
response may be induced to enhance resistance against
oncovirus-associated tumors.
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Introduction
The majority of tumor viruses are well controlled by the
immune system and therefore cause only transient or no
disease in their hosts after infection. It is apparent that the
main role in this control can be ascribed to the presence of
cytotoxic CD8? T cells, which are very effective in
destroying virus infected or transformed cells. In recent
years, the idea that CD4? T cells can also play a consid-
erable role in protective anti-tumor responses has received
growing attention. One important function of CD4? T cells
is their help for CD8? T cell and antibody responses
against virus or tumor antigens. However, studies using
several tumor models have shown that CD4? T cells can
efficiently eliminate major histocompatibility complex
(MHC) class II expressing tumor cells [1, 2] as well as
tumors lacking MHC class II molecules [3–5], demon-
strating a direct role of CD4? T cells in tumor rejection.
However, whether CD4? T cells can fully compensate for
the effector functions of CD8? T cells in the control of
virus-induced tumors remains unclear. In addition, the
significance of regulatory T cells (Tregs) in inhibiting
tumor-specific CD4? T-cell responses during tumor rejec-
tion in vivo has not been defined. It was previously
reported that Tregs infiltrate tumors and draining lymph
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nodes, suggesting that they interfere with anti-tumor
immune responses in general and thereby contribute to
tumor growth and progression [6]. Tregs inhibit the func-
tion of many adaptive and innate immune cells, including
CD4? T cells, CD8? T cells, dendritic cells (DCs), mac-
rophages, natural killer (NK) cells, and B cells through
various molecular mechanisms [7]. To define the role of
Tregs in tumor immunity, most studies have used malig-
nant tumor models, in which the immune system failed to
prevent tumor progression. However, the task of effector
CD4? T cells and Tregs should also be analyzed in
effective anti-tumor immunity to fully understand their role
in tumor biology.
To address these questions, we have used the Friend
retrovirus (FV)-induced mouse tumor cell line of C57BL/6
origin, called FBL-3 cells [8]. This cell line was generated
by inoculation of FV complex into mice, which results in
an EPO receptor-dependent proliferation signal in ery-
throid precursor cells. Integration of pro-virus can subse-
quently cause over-expression of the Spi1 proto-oncogene
and inactivation of the p53 tumor suppressor gene resulting
in host cell transformation. Thus, FV infection can induce
fully malignant erythroleukemia in susceptible mouse
strains. FBL-3 is a FV-transformed tumor cell line that
does not produce infectious virus, but expresses highly
immunogenic FV antigens [9, 10]. After subcutaneous
(s.c.) implantation of FBL-3 cells into mice, the tumor
grows locally and subsequently regresses in a CD8? T-cell-
dependent manner over a time period of 20 days [11, 12].
Tumor-specific CD4? T cells seem to be less important
for tumor rejection when functional CD8? T cells are
present [13]. However, if the pool of Tregs is expanded
by a chronic infection, mice fail to reject transplants of
FBL-3 tumors due to a Treg-mediated suppression of
tumor-specific CD8? T-cell responses [11]. In the pres-
ent study, we used Foxp3 (forkhead box P3) transgenic
mice expressing the diphtheria toxin (DT) receptor under
the control of the Foxp3 promoter, which made it pos-
sible to selectively deplete Tregs in vivo and to deter-
mine the influence of Foxp3? Tregs on T-cell responses
during tumor regression. We especially focused on the
direct anti-tumor effect of CD4? T cells and found that
these cells could fully compensate for the lack of cyto-




Experiments were done using sex- and age-matched
C57BL/6 (B6), CD45.1, and DEREG [14] mice that were
between 8 and 10 weeks old when experiments started.
Mice were housed in specific pathogen-free conditions and
treated in accordance with institutional guidelines.
Cell lines
FBL-3 is an FV-induced tumor cell line derived from a
C57BL/6 mouse [8]. The highly immunogenic FBL-3 cell
line expresses FV antigens but does not produce infectious
virus. FBL-3 cells were maintained in complete RPMI
medium supplemented with 10 % FCS and 0.5 % penicil-
lin/streptomycin.
Tumor challenge
1 9 107 FBL-3 tumor cells were injected s.c. on the right
flank in 100 ll of PBS through a 27-gauge needle on day 0.
In order to verify tumor volume by external caliper, the
greatest longitudinal diameter (length) and the greatest
transverse diameter (width) were determined. Tumor size
based on caliper measurements was calculated by the for-
mula: tumor area (cm2) = p 9 a 9 b, where a = half of
length and b = half of width. After 4, 6, 8, 11, 15, and
20 days, mice were killed, and tumors and draining and
non-draining lymph nodes were resected.
In vivo cell depletion
CD8 depletion was performed as described [15] and started
at day 0 and carried out every other day for the tumor
growth analysis until mice were killed due to the pro-
gressive tumor growth, and four times (on days 0, 2, 4, 6)
for the experiments where mice were killed at day 6 post-
tumor inoculation. Depletion of Tregs was done as
described [16] and started at day 1 for three times.
Depletion of CD4? T cells was performed as described
[17] and started at day 0. Deletion of NK cells was carried
out as described [15].
Staining and flow cytometry
Antibodies used for cell-surface staining were anti-CD4
(AF 700-conjugated, GK 1.5), anti-CD8a (eFluor 450-
conjugated, 53–6.7), anti-CD43 (PerCP-conjugated, 1B11),
anti-CD25 (PE Cy7-conjugated, PC61.5), anti-Mac-1 (anti-
CD11b) (FITC-conjugated, WT.5), anti-F4/80 (PE-conju-
gated, BM8), anti CD86 (eFluor 605-conjugated, GL-1),
and Fc block anti-mouse CD16/CD32 (93) (eBioscience).
Dead cells were excluded by using propidium iodide.
Intracellular granzyme B (GzmB) staining was performed
as described [18]. To determine intracellular production of
interferon-c (IFN-c), tumor necrosis factor-a (TNF-a) and
interleukin-2 (IL-2) cells from lymph nodes were
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stimulated in the presence of 2 lg/ml of CD28 antibody
and 2 lg/ml of brefeldin A for 5 h at 37 C. The cells were
then stained for surface expression of CD4, CD8, and
CD43, fixed, and permeabilized with Cytofix/Cytoperm
solution (BD). The cells were then washed, permeabilized,
and incubated with Fc blocking anti-mouse CD16/CD32.
After that, cells were labelled with monoclonal antibodies
specific for IL-2, IFN-c, TNF-a, and anti-CD154. In addi-
tion to cytokines, cells were labeled with anti-CD154 (PE-
conjugated, CD40Ligand, gp39, MR1). Foxp3 expression
was detected by intracellular staining using an anti-mouse/
rat Foxp3 antibody (FITC-conjugated, FJK-16s) and the
Foxp3 staining kit (eBioscience). Helios expression was
measured by intracellular staining using an anti-mouse/
human Helios antibody (eFluor 450-conjugated, 22F6,
BioLegend) and the Foxp3 staining kit (eBioscience). Dead
cells were excluded by using Fixable Viability Dye
(eBioscience). Data were acquired on an LSRII flow
cytometer (Becton–Dickinson) from 200,000 to 500,000
lymphocyte-gated events per sample. Analyses were done
using FACSDiva software (Becton–Dickinson) and FlowJo
software (Treestar).
In vivo cytotoxicity
The in vivo cytotoxicity assay was done as it was described
by Barber et al. [19]. Tumor-bearing DEREG mice were
depleted or not depleted for their Treg and CD8? T cells.
Six days after tumor challenge, all groups of mice received
Carboxyfluorescein succinimidyl ester (CFSE)-labeled
lymphocyte targets loaded with peptide [20] as well as
unloaded unstained cells from CD45.1 mice as a control
population. 2 h after intravenous (i.v.) injection of donor
cells, mice were killed and in vivo killing activity was
quantified in single-cell suspensions from the drLN of each
tumor-bearing mouse.
Immunohistochemistry
Tumors were dissected sharply using surgical scissors,
immediately shock-frozen in liquid nitrogen and stored at
-80 C. The frozen tissues were sectioned in 5 lm slices,
placed on slides, air-dried, and stained with hematoxylin–
eosin.
Frozen samples were air-dried and fixed with Cytofix/
Cytoperm (BD, Heidelberg, Germany). Endogenous per-
oxidase activity was blocked with Dako REAL Peroxidase-
Blocking solution (DakoCytomation, Hamburg, Germany)
followed by several washing steps with PBS. Slides were
incubated for 60 min with the primary monoclonal rat anti-
mouse antibodies anti-CD11b antibody (BioSource,
Solingen, Germany) or anti-CD4 antibody (BD Bioscience,
Heidelberg, Germany). Subsequently, samples were incubated
with peroxidase-conjugated rabbit anti-rat (Dianova, Ham-
burg, Germany) and goat anti-rabbit antibodies (Dianova) for
30 min each and AEC Single Solution (Invitrogen). Nuclei
were visualized by Shandon Instant Hematoxylin (Thermo
Fisher Scientific). Sections were analyzed with a Zeiss Axio-
scope 2 (Carl Zeiss, Oberkochen, Germany) using objective
lenses with 2009 magnification and AxioVision software
(Zeiss).
Tetramer staining
MHC class I and class II tetramer staining was performed
as described [17].
Statistical analyses
Statistical analyses and graphical presentations were com-
puted with Graph Pad Prism version 5. Statistical differ-
ences (P value) between two groups were calculated using
unpaired t test. Statistical differences (P value) between the
different parameters were calculated testing with the
Kruskal–Wallis one-way analysis of variance on ranks and
Newman–Keuls multiple comparison tests.
Results
Kinetics of the antigen-specific CD4? and CD8? T-cell
response in lymph nodes during tumor rejection
To study T-cell responses in tumor cell rejection, we used
the leukemia cell line FBL-3, a FV-induced tumor line
from a C57Bl/6 mouse. These highly immunogenic murine
leukemia cells induce local tumor growth after s.c. injec-
tion into C57/Bl6 mice for about 20 days before being
rejected due to IFN-c and granzyme-producing CD8? T
cells [11]. It has been shown that FBL-3 tumor cells
express FV antigens that can be recognized by CD8? and
CD4? T cells [9, 10]. To determine the kinetics of T-cell
responses in this tumor rejection model, we quantified the
population of FV-specific effector CD8? T cells by stain-
ing lymphocytes from draining (drLN) and non-draining
lymph nodes (non-drLN) of FBL-3-challenged mice with
H-2DbgagL MHC class I tetramers [9, 20] or MHC class II
tetramers loaded with the H-2I-Ab-restricted CD4? T-cell
epitope H19-Env [20]. Early after tumor challenge (4 days
post-tumor challenge (ptc)), expansion of specific cells was
only found in the CD4? but not the CD8? T-cell popula-
tion (Fig. 1a, b). Thus, the frequencies of antigen-specific
CD4? T cells in drLN at day 4 ptc were significantly higher
compared to specific CD8? T cells (Fig. 1c). Peak expan-
sion of specific CD4? T cells was found as early as at
6 days post-tumor challenge, whereas CD8? T-cell
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expansion reached its maximum 2 days later (Fig. 1a, b).
For both T-cell populations, the contraction phase began at
day 15 ptc. A comparison between different lymph nodes
showed that the specific CD4? and CD8? T-cell responses
were generally located in drLN as the peak expansion of T
cells was significantly higher in drLN than in non-drLN.
However, a modest increase in the percentage of specific
CD4? and CD8? T cells was also observed in non-drLN
compared to lymph nodes cells from naı¨ve animals
(Fig. 1a, b). Collectively, the data demonstrate a local
expansion of tumor-specific T cells with the CD4? T-cell
response developing more rapidly than the CD8? T-cell
response.
Functional activity of the tumor-specific CD4?
and CD8? T cells
Next, we wanted to analyze functional properties of CD4?
and CD8? T cells during tumor rejection. To this end, we
performed kinetic analysis of cytokine and granzyme B
(GzmB) expression in T cells after tumor challenge. To
analyze the total populations of CD4? and CD8? T cells
that were activated during tumor rejection, we used the
maker CD154 (CD40L) for CD4? T cells [21] and the
activation-associated glycoform of CD43 for CD8? T
cells [22]. In order to exclude Tregs from the effector
CD4? T-cell pool, we also stained for intracellular
expression of Foxp3. In drLN nodes, the highest fre-
quency of CD4? T cells producing the three cytokines
IFN-c, TNF-a, and IL-2 was found between day 4 and 6
ptc (Fig. 2a). At day 8 ptc, the cytokine response already
started to decrease, which was earlier than the decline in
tetramer II-positive CD4? T cells (Figs. 1a, 2b). The
frequency of CD4?CD154? T cells producing the three
cytokines was significantly higher in drLN than in non-
drLN (Fig. 2b and supplementary figure S1, available
on-line), which correlated with the increased percent-
ages of tetramer-positive CD4? T cells in drLN (Fig. 1a).
Fig. 1 Kinetics of FBL-3-specific effector CD4? and CD8? T-cell
responses: B6 mice were inoculated s.c. with 1 9 107 FBL-3 cells
(n = 9–12 mice per group). Mean percentages ± SEM of FBL-3-
specific CD4?TetII? T cells reactive with I-Ab MHC class II
tetramers specific for FV-Env epitope (a) and effector CD8? T cells
reactive with MHC class I H-2Db tetramers specific for the FV gagL
CTL epitope (b) in draining (white box plots) and non-draining (grey
box plots) lymph nodes. The mean percentage for each group is
indicated by a line. c Expansion of antigen-specific CD4 T cells in
draining lymph nodes at day 4 ptc is shown. Each dot represents an
individual mouse, and the mean numbers are indicated by a line. All
tetramer-positive T cells expressed cell-surface activation marker
CD43. Statistically significant differences between the groups are
given in the figures. The experiment was repeated three times with
comparable results
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The peak cytokine production by CD8? T cells in drLN
was found at day 8 ptc again showing the delay in the
CD8? T-cell response compared to CD4? T cells (Fig. 2a,
c). In addition, the numbers of CD8?CD43? T cells
producing cytokines were much lower than those of
activated CD4? T cells. No cytokine production by CD8?
T cells was found in non-drLN during tumor rejection
(data not shown). As expected, the cytotoxic molecule
GzmB was also produced by CD8?CD43? T cells after
tumor challenge (Fig. 2d). The peak of this functional
response was found between day 8 and 11 ptc. Remark-
ably, tumor-induced activation of Foxp3- CD4? T cells
in drLN also resulted in their differentiation into GzmB-
producing cells, suggesting a potential cytotoxic role for
these cells. Peak GzmB expression in CD4?CD43? T
cells was observed at day 6 ptc, which was again earlier as
in the CD8? T-cell compartment. Thus, both CD8? and
CD4? T-cell populations in drLN expressed pro-inflam-
matory cytokines and GzmB in response to tumor chal-
lenge, but the CD4? T-cell response initiated earlier and
the magnitude of the response was higher than the CD8?
T-cell response.
Kinetics of the local Treg response during tumor
rejection
Since Tregs were reported to have a suppressive role in the
control of local tumor immune responses [6], we next
assessed the significance of these cells in rejection of the
FBL-3 tumor cells. To this end, the kinetics of Treg
responses in drLN and non-drLN were compared. To dis-
tinguish between Treg and effector CD4? T-cell popula-
tions, we utilized the unique Treg marker Foxp3.
Interestingly, in non-drLN, the frequency of Foxp3? Tregs
started to increase at day 4 ptc and stayed elevated until
day 20 ptc in comparison with naı¨ve animals (Fig. 3a). In
contrast, in drLN Treg, frequencies decreased on day 4 ptc
and remained reduced until day 15 ptc. This was a sur-
prising finding since we knew from previous studies in the
FV model that Tregs expand at the side of inflammation
during a chronic virus infection [16]. One possible expla-
nation was that these cells leave the drLN and migrate into
the tumor microenvironment. To address this, tumor-infil-
trating lymphocytes (TIL) were isolated and examined for
Treg frequencies. From the TIL, a mean of 38 % Tregs was
Fig. 2 Cytokines and functional properties of T cells: B6 mice were
inoculated s.c. with 1 9 107 FBL-3 cells. At different time points ptc,
lymphocytes from lymph nodes were isolated and investigated.
Kinetics of IFN-c-, TNF-a-, and IL-2 expressing CD154?CD4?
(a) and CD43?CD8? (c) T cells from lymph nodes are shown.
b Numbers of cytokine producing CD4?CD154? T cells at day 6 ptc
are depicted. Each dot represents an individual mouse and the means
are indicated by a line. d Intracellular expression of GzmB. Numbers
of CD8?CD43? (white box plots) and CD4?Foxp3- (grey box plots)
T cells producing GzmB are shown in drLNs at different days ptc.
Differences between two groups are indicated (*P \ 0.05,
**P \ 0.005, ***P \ 0.0005). All experiments were repeated three
times with comparable results
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found at 6 days ptc, whereas only a mean of 13 % Tregs
was found in drLN, suggesting an infiltration of Tregs from
the drLN into the tumor microenvironment.
One of the most potent mechanisms of Treg-mediated
effector T-cell suppression is the direct killing of effector
cells by the granzyme/perforin pathway [23, 24]. Thus, we
examined the production of GzmB in CD4?Foxp3? Tregs.
In drLN, Tregs started to produce GzmB at 4–6 days ptc
(Fig. 3c) and the frequency of GzmB-producing Tregs
correlated with the kinetics of the overall CD4? T-cell
response (Fig. 1a). In contrast, in non-drLN, FBL-3 chal-
lenge did result in only slight expansion of GzmB-pro-
ducing Tregs at day 8–15 ptc (Fig. 3c). To analyze whether
the GzmB? Tregs were natural (nTregs) or induced Tregs
(iTregs), we stained for the nTreg marker Helios, a member
of the Ikaros transcription factor family [25, 26]. The vast
majority of the granzyme-producing Tregs expressed
Helios (Supplementary figure S2, available on-line), sug-
gesting that those cells were mostly thymic-derived nTregs.
The role of different T-cell populations in the control
of tumor growth
It was previously reported that CD8? T cells are essential
in controlling FBL-3 progression, whereas CD4? T cells
did not affect the tumor growth [11, 13]. In agreement with
these previous studies, tumor regression was completely
abrogated when CD8? T cells were ablated by monoclonal
antibodies (Fig. 4b). In contrast, the depletion of CD4? T
cells did only temporary increase the tumor size at 6 days
ptc but did not affect the subsequent rejection of FBL-3
tumor cells (Fig. 4c). The data demonstrate that mainly
CD8? T cell-mediated rejection of FBL-3 tumor cells but
CD4? T cells had only a minor effect. However, the
influence of Tregs on the different effector T-cell popula-
tions during tumor rejection is poorly understood. To
investigate this influence, we studied tumor regression and
T-cell functions after selective depletion of Tregs. We used
transgenic DEREG mice, which express a diphtheria toxin
(DT) receptor under control of the Foxp3 promoter. An
injection of DT selectively depleted more than 90 % of the
Tregs (data not shown). No other cell population was
depleted by this treatment. Interestingly, DT treatment of
tumor-bearing DEREG mice did not significantly improve
tumor elimination (Fig. 4d). Thus, in a tumor model in
which immune surveillance and immune control are
effectively mediated by tumor-specific CD8? T cells, these
cells do not seem to be functionally suppressed by Tregs.
This is in line with our finding that depletion of Tregs did
not enhance FBL-3-specific cytotoxicity of CD8? T cells in
an in vivo CTL assay with target cells loaded with a Friend
virus immunodominant epitope peptide [9] (Fig. 4h).
However, these results did not indicate whether or not
tumor-specific CD4? T-cell responses were suppressed by
Fig. 3 Regulatory T cells in
lymph nodes: B6 mice were
inoculated s.c. with 1 9 107
FBL-3 cells on day 0.
a Numbers of CD4?Foxp3? in
drLNs and non-drLNs are
shown. b Representative
histograms display Foxp3
expression among CD4? T cells
in lymph nodes and tumor at
day 6 ptc [Tumor-infiltrating
lymphocytes (TILs)]. Numbers
indicate percentages within the
respective Foxp3? gate.
c Numbers of CD4?Foxp3? T
cells producing GzmB in lymph
nodes are shown. Each dot
represents an individual mouse,
and the mean numbers are
indicated by a line. The
experiment was repeated three
times with comparable results
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Tregs. To clarify this, we depleted Tregs and CD8? T cells
at the same time in tumor-bearing mice. Whereas CD8?
T-cell ablation alone resulted in progressive tumor growth
(Fig. 4b), additional Treg depletion enabled the mice to
again reject the tumor (Fig. 4e). The only difference to
non-depleted wild-type mice was that the FBL-3 tumors
increased in size for up to 4 days longer before they were
rapidly rejected. To exclude a possible role of NK cells, the
additional depletion of those cells in the group of mice
lacking Tregs and CD8? T cells was performed (Fig. 4f).
Such mice could still reject the tumor, demonstrating that
NK cells had no effect on tumor rejection in CD8?-
depleted mice. In order to demonstrate that tumor rejection
in mice depleted for CD8? T cells and Tregs (Fig. 4e) was
due to effector CD4? T-cell responses, tumor growth was
tested in mice lacking both CD4? (including Tregs) and
CD8? T cells. In the absence of these T-cell compartments,
no control of tumor growth was observed (Fig. 4g). This
experiment suggests that CD4? T cells can mediate potent
anti-tumor effects when cytotoxic CD8? T cells are absent
but that they are tightly controlled in their activity by
Foxp3? Tregs.
Fig. 4 Influence of different
cell populations on tumor
formation: Effects of no
depletion (injected with PBS)
(a), depletion of CD8? T cells
(b), CD4? T cells (c), Tregs (d),
CD8? and Tregs (e), CD8?, NK
cells and Tregs (f) and CD4?
and CD8? T cells (g) are shown.
DEREG mice were injected s.c.
with 1 9 107 FBL-3 cells
(1 9 107) and tumor size was
measured. Mice were depleted
for their CD8?, CD4? T cells,
and Tregs as described in
‘‘Materials and methods.’’ Each
line represents tumor
progression in an individual
mouse. h In vivo killing activity
of CD8? T cells in different
treatment of mice. Mean
percentages show killing of
cells loaded with the FV
DbgagL peptide in an in vivo
CTL assay (described in
‘‘Materials and methods’’
section) at day 6 ptc in DEREG
mice treated or not treated with
DT. Data were pooled from four
to six independent experiments
with similar results. P values
were determined by an unpaired
t test (n.s., non-significant).
Dragger symbol mice were
euthanized due to progressive
tumor growth
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The impact of Tregs on the functions of tumor-specific
CD4? T cells
To prove that Tregs indeed control anti-tumor CD4? T-cell
functions in the FBL-3 model, we analyzed numbers of
tumor-specific CD4? T cells, their cytokine production and
cytotoxic activity after Treg ablation with or without
additional CD8? T-cell depletion. In DT-treated DEREG
mice challenged with tumor cells for 6 days, we observed a
significant increase in the mean percentage of tumor-spe-
cific (tetramer II?) CD4? T cells in comparison with mice
that received only FBL-3 cells (Fig. 5a). Moreover, if
depletion of Tregs was combined with CD8? T-cell
removal, the CD4? T-cell response was further significantly
enhanced. CD8? T-cell depletion alone did not influence
the mean percentage of tumor-specific CD4? T cells, sug-
gesting that their expansion was mainly controlled by Tregs
(Fig. 5a). Tregs did not only influence CD4? T-cell
expansion but also modified their functional properties. In
DT-treated mice, significantly more CD4?CD154? T cells
expressed the cytokines IFN-c, TNF-a, and IL-2 than in
mice receiving only tumor cells (Fig. 5b). Dual depletion of
Fig. 5 The influence of
regulatory T cells on tumor-
specific CD4? T-cell functions:
DEREG mice were inoculated
s.c. with 1 9 107 FBL-3 cells
on day 0. One day before tumor
inoculation, some mice also
received DT to deplete Foxp3?
Tregs, and day later monoclonal
antibody to deplete CD8? T
cells. At day 6 post-tumor
transplantation, lymphocytes
from draining lymph nodes
were analyzed. a The
percentages of CD4? T cells
reactive with I-Ab MHC class II
tetramers are shown. Numbers
of CD4?CD154? T cells
producing cytokines (IFN-c,
TNF-a, and IL-2) are shown (b).
Numbers of activated (positive
for the activation-induced
isoform CD43) CD4?Foxp3- T
cells producing GzmB (c) and
representative dot plots of
GzmB and tetramer II
expression (d) in different
treatment of mice are shown.
Differences between two groups
are indicated (*P \ 0.05,
**P \ 0.005). Results were
obtained from three experiments
with comparable results
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Tregs and CD8? T cells resulted in slightly higher mean
frequencies of cytokine producing CD4? T cells than after
Treg deletion alone but this difference was only significant
for IL-2-producing cells (Fig. 5b). To determine possible
cytotoxic effects against FBL-3 tumor cells, production of
the cytolytic molecule GzmB by activated (CD43?) CD4?
T cells was analyzed. In mice lacking Tregs, the frequency
of GzmB-positive cells was significantly higher compared
to non-depleted tumor-bearing mice (Fig. 5c, d). Additional
ablation of CD8? T cells together with the Tregs resulted in
a significant rise in the mean frequencies of GzmB? CD4?
T cells in comparison with mice only depleted for Tregs
(Fig. 5c). Again, CD8? T-cell depletion alone did not
influence the functional CD4? T-cell response during tumor
rejection (Fig. 5c, d).
The cytotoxic potential of tumor-specific
CD4? T cells in vivo
To analyze whether the increased expression of GzmB
correlated with improved tumor-specific lysis of target
cells after Treg depletion, we performed a series of in vivo
killing experiments. The in vivo killing activity was
quantified in the drLN of each mouse during tumor rejec-
tion. In non-depleted animals, CD4? T cells showed a
modest in vivo killing activity not exceeding a mean of
13 % target cell lysis (Fig. 6a). Surprisingly, depletion of
Tregs alone did not significantly improve the lysis of target
cells. In contrast, simultaneous ablation of CD8? T cells
and Treg significantly enhances the killing of peptide-loa-
ded cells (Fig. 6a, b), which correlated with the high fre-
quency of GzmB-producing cells in this group of mice
(Fig. 5c, d). Notably, in this group, tumor growth was
completely rejected even in the absence of CD8? T cells
(Fig. 4e). To demonstrate that cytotoxic CD4? T cells
mediated the target cell killing in the group of CD8? T cell
plus Treg depleted mice, we additionally depleted the
effector CD4? T cells. This completely abrogated the
MHC II-restricted killing activity (Fig. 6a). Collectively,
these data suggest that CD4? T cells can gain cytotoxic
activity against tumor cells when CD8? T cells are not
active but this activity is tightly controlled by Tregs during
tumor rejection.
Upregulation of MHC class II molecule on FBL-3
cells in vivo
The level of MHC II expression directly influences
T-lymphocyte activation and recognition of target cells by
CD4? T cells. It has been published previously that CD4?
T cells cannot directly recognize FBL-3, since they only
express MHC class I but no MHC class II molecules [27].
However, our in vivo experiments strongly suggest a
cytotoxic activity of CD4? T cells against FBL-3 tumors.
Therefore, the MHC class II expression of FBL-3 tumor
cells extracted directly from tumor-bearing mice was
analyzed. As expected, no MHC class II molecules were
found on FBL-3 cells from cell culture (Supplementary
figure S3a, available on-line). To study MHC class II
expression in vivo and to distinguish the FBL-3 from
tumor-infiltrating cells, CD45.1 transgenic mice were used.
In these mice, all leukocytes express the CD45.1 alloanti-
gen and therefore can be excluded by the surface staining.
Interestingly, after being in the host environment, the
phenotype of the FBL-3 cells had partially changed. A
proportion of 14 % of the inoculated MHC II-deficient
Fig. 6 In vivo killing activity of CD4? T cells after different
treatment of mice: Mean percentages of killing (a) and representative
histograms (b) of in vivo CTL assay are depicted. Tumor-bearing
mice were depleted for their Tregs alone or additionally for their
CD8? T cells. Target cells from donor CD45.1 mice (CFSE? and
CFSE-) were co-transferred i.v. in the same amount into tumor-
bearing mice. CFSE? cells were loaded with the class II-restricted
peptide recognized by CD4? T cells, whereas CFSE- cells were used
as a control population 2 h later, lymphocytes were isolated from the
draining lymph nodes and analyzed by flow cytometry to determine
the percentage of remaining target cells that are either CFSE? or
CFSE-. Each dot represents an individual mouse, and the mean
percentages are indicated by a line. Differences between two groups
are indicated (*P \ 0.05). All experiments were repeated two times
with comparable results
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FBL-3 cells became I-Ab-positive after 4 days ptc in CD45.1
mice (Supplementary figure S3b, available on-line). These
MHC-II-expressing FBL-3 cells could be a possible target
for cytotoxic CD4? T cells and might explain part of the CD4?
T-cell-mediated FBL-3 tumor rejection (Fig. 4e).
The role of macrophages in FBL-3 tumor growth
It is well known that macrophages can contribute to tumor
rejection. We therefore focused our study on the role of
these cells in FBL-3 tumor growth. Since tumor-bearing
mice depleted for CD8? T cells and Tregs showed com-
plete tumor rejection, we analyzed in this group for
CD11b?F4/80? macrophage activation (expression of
CD86 [28]) at day 6 ptc in lymph nodes in comparison with
non-depleted and naı¨ve animal. Significant expansion of
CD11b?F4/80? macrophages from drLNs but not in non-
drLNs was observed (Fig. 7a). Depletion of CD8? T cells
and Tregs also promoted the upregulation of the costimu-
latory molecule CD86, which indicated macrophage acti-
vation (Fig. 7b). Interestingly, activated macrophages did
not produce granzyme B (data not shown). However,
Fig. 7 The role of macrophages in FBL-3 tumor growth: DEREG
mice were inoculated s.c. with 1 9 107 FBL-3 cells on day 0. One
day before tumor inoculation, some mice also received DT to deplete
Foxp3? Tregs and day later monoclonal antibody to deplete CD8? T
cells. At day 6 post-tumor transplantation, leukocytes from drLNs and
non-drLNs were analyzed. Numbers of CD11b?F4/80? cells are
shown (a). Numbers of CD11b?F4/80?CD86? (b) and
CD11b?TRAIL? (c) cells are shown. Experiments were repeated
twice with similar results. Differences between two groups are
indicated (***P \ 0.0005). The infiltration of CD4? T cells and
CD11b? macrophages into the tumor is shown by immunohistology
(d) (magnification 9200)
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significantly increased expression of the TNF-related
apoptosis-inducing ligand (TRAIL) that can induce tumor
cells apoptosis [29] was detected on macrophages from
drLNs of mice depleted for CD8? T cells and Tregs
compared to non-depleted controls (Fig. 7c). These data
were in line with the immunohistochemistry of tumors
from the dual depleted group that showed infiltration of
CD11b? macrophages in the tumor mass in addition to
CD4? T-cell infiltration (Fig. 7d).
Discussion
The CD4?-helper T-cell response represents a critical part
of a functional immune system and is well characterized in
many tumors but its effector role in the control of virus-
induced tumors remains unclear. In the current research, we
have used a highly immunogenic FV-induced tumor cell
line of C57BL/6 mouse origin, namely FBL-3 cells, as a
model to study the mechanisms of immunological control
and escape during tumor formation. Our studies show that
when CD8? T cells were unable to control FBL-3 tumor
development, cytotoxic effector CD4? T cells were able to
take over and eliminate the tumor. However, direct anti-
tumor effects of CD4? T cells were strictly regulated by
Tregs, which thereby contributed toward tumor progression.
Here, we compared the kinetics of the CD4? T-cell
response to FBL-3 tumor antigen in drLN with the CD8?
T-cell response and found a more rapid development of the
CD4? T-cell response after FBL-3 injection. Peak expan-
sion of tumor-specific CD4? T cells was observed 2 days
later as the CD8? T cell. In contrast, in a virus infection
model with FV peak tetramer-positive CD8 T-cell,
responses were far greater in magnitude [18, 30] than peak
tetramer-positive CD4 T-cell responses [17]. In previous
studies using the Moloney murine sarcoma and leukemia
virus complex (MoMSV), which share the immunodomi-
nant CD4? and CD8? T-cell epitopes with FV, the burst
size of the virus-specific CD8? T-cell response was con-
siderably larger than that of virus-specific CD4? T cells in
drLNs [20].
Immune escape of tumors has been studied in many
models and has in part been attributed to active suppression
mediated by CD4?Foxp3? Tregs [31]. The drLN is the site
of the critical decision between immune activation and
tolerance and has a major influence on host immunity. The
current study shows that the Tregs from the drLNs appear
to migrate into the tumor and influence the local micro-
environment. The influence of Treg localization (sentinel
lymph nodes and tumor) on cancer progression is still
disputed [32–35]. The assessment of circulating Tregs or
Tregs infiltrating the tumor itself has been used as a
prognostic indicator in human cancers but conflicting
results were obtained in different tumor diseases. Curiel
et al. [32] reported that the presence of high numbers of
CD4?CD25?Foxp3? cells in malignant ascites of ovarian
carcinoma correlated with tumor staging and reduced sur-
vival. In colorectal cancer patients, it was demonstrated
that Tregs in drLNs correlated better with disease pro-
gression and tumor stage [33]. Another observation in
breast carcinoma indicated that Treg localized within
lymphoid aggregates, but not in the tumor area, had a
negative impact on patients’ survival [34]. The finding
agrees with animal models of colon cancer [36] and goes in
line with our study. This suggests that Tregs in the drLNs
can inhibit the development of effector cells such as
cytotoxic CD4? and CD8? T cells, whereas Tregs in the
tumor itself may have dual functions of controlling tumor-
promoting inflammation on one hand but suppressing local
effector T-cell responses on the other [37]. Thus, in studies
aimed at analyzing the impact of Tregs on tumor pro-
gression, it is critical to take the localization of Foxp3?
Treg into account.
Although the perforin/granzyme pathway was previ-
ously known to be utilized by CD8? T cells and NK cells
to lyse target cells, recent studies have suggested that Tregs
may also use perforin/granzyme-mediated cytotoxicity as a
mechanism to kill conventional T cells [23, 24]. In our
study, we showed that after FBL-3 challenge, Tregs in the
drLNs started to produce GzmB. Moreover, the frequency
of GzmB-producing Tregs correlated with the kinetics of
the effector CD4? T-cell response. This observation and
data from Treg depletion experiments strongly suggest that
GzmB-producing Tregs suppress anti-tumor CD4? T-cell
responses. Grossman et al. [38] showed that activated
human Tregs expressed granzyme A and/or B and could
kill activated CD4? and CD8? T cells. This Treg-mediated
killing was perforin-dependent [38]. Similarly, Gondek
et al. [23] reported that murine Tregs stimulated with anti-
CD3 mAb expressed GzmB and could suppress conven-
tional CD4? T cells in a cell contact and GzmB-dependent
manner. Using a system of tumor inoculation and adoptive
transfer of Tregs, it was shown that GzmB was highly
induced in tumor-associated Tregs by local factors in the
tumor microenvironment [39]. Thus, cytotoxic activity of
Tregs might be a general mechanism of Treg-mediated
suppression in tumor development. Interestingly, this is
different to Treg activity in chronic infectious diseases in
which most activated Tregs do not express granzymes [16].
It was previously reported that CD8? T cells are
essential in controlling FBL-3 progression [11, 12]. After
administration of anti-CD8 mAb, rejection of local tumors
induced by FBL-3 challenge was blocked and mice died
from systemic lymph node metastases [12]. In agreement
with these previous studies, we showed that the absence of
CD4? T cells during FBL-3 formation did not significantly
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influence the tumor growth [13]. Although we found a very
potent and rapid CD4? T-cell response (production of
cytokines and cytotoxins), these cells had only a minor
effect on FBL-3 tumor rejection. Most likely, a direct anti-
tumor effect of CD4? T cells is not required in a system in
which the cytotoxic function of CD8? T cells is sufficient
to mediate the successful rejection of the tumor. However,
effector CD4? T cells could replace cytotoxic CD8? T
cells but they were under tight regulation by Tregs. While
CD8? T-cell ablation alone resulted in uncontrolled tumor
growth [12, 13], additional Treg depletion enabled the
CD4? T cells to reject the tumor. Control experiments
showed that this anti-tumor effect was exclusively medi-
ated by effector CD4? T cells (Fig. 4g). To define the
suppressive effects of Tregs on conventional T cells, one
has to take their functions on CD4 and CD8 populations
into account. Our current study shows that Treg depletion
had no biological effect on CD8? T-cell-mediated tumor
rejection. Although CD8? T-cell functions were aug-
mented after Treg depletion (data not shown), this did not
result in faster tumor rejection, most likely because the
antitumor CTL were very efficient even under the sup-
pressing influence of Tregs. In contrast, in FV infection, the
functional suppression by Tregs mainly targeted CD8? T
cells [40], resulting in the development of functional
exhausted CD8? T cells and in high FV loads in lymphatic
organs [16]. Earlier Iwashiro et al. [11] demonstrated that
mice persistently infected with FV have approximately
twice the normal percentage of splenic CD4?CD25? Tregs
and lose their ability to reject the implantation of FBL-3
cells. In a mouse model of spontaneous mammary carci-
noma, the depletion of Tregs resulted in CD4? T-cell
activation and subsequent development of efficient CD8?
T-cell activity [41]. In two other models of antitumor
immunity, it was proposed that Tregs diminished CD8?
T-cell function by consuming IL-2 [42] or by preventing
cytotoxic granule release [43]. In a model of autoimmunity,
other authors proposed that DCs were central to Treg
inhibition in vivo and attenuated priming of CD4-helper
cells [44]. Hence, it seems to depend on the environment
and the type of immunity whether Tregs preferentially
regulate CD4? or CD8? T-cell populations. In addition, the
specificity of Treg depletion might also influence the
results in certain experiments. The use of non-specific Treg
targeting agents such as CD25-depleting antibodies, which
in addition to CD25? Tregs also deplete recently activated
CD25? effector T cells, can complicate the interpretation
of the data. In our study, we used transgenic DEREG mice,
which express a diphtheria toxin receptor under the control
of the Foxp3 promoter, allowing highly selective depletion
of Foxp3?Tregs even during ongoing immune responses
[45]. Our finding that Tregs preferentially influence the
anti-tumor CD4? T-cell immune response revealed several
aspects that had not been reported previously. The CD4? T
cells residing in the drLNs of mice depleted of Tregs and
CD8? T cells showed major changes to those of non-
depleted mice. We demonstrated that in vivo depletion of
Tregs and CD8? T cells in FBL-3-bearing DEREG trans-
genic mice augments GzmB production by CD4? T cells
and increases FV-specific CD4? T-cell effector and cyto-
toxic responses leading to the complete tumor regression.
Therefore, the Foxp3? Tregs control the proliferation and
function of effector CD4? T cells and prevent the induction
of efficient CD4? T cells with cytotoxic potential. It was
previously shown that in the murine mammary carcinoma
model, deletion of Tregs resulted in increasing numbers of
IFN-c and IL-2-producing CD4? T cells at tumor sites [41].
However, the CD4? T cells alone, even in the absence of
Treg suppression, were not sufficient to abrogate tumor
progression [41] but the Treg removal was performed by
using anti-CD25 antibodies and depletion of Tregs was
incomplete [41]. Another group has also used DEREG
mice for selective depletion of Tregs [46]. However, the
regression of the melanoma growth, which was induced by
depletion of Foxp3? Tregs, was critically dependent on the
presence of CD8? T cells in this model and additional
elimination of those cells resulted in ongoing tumor pro-
gression [46].
We show here that the immune system may still be
capable of controlling tumor development in the absence of
the main cytotoxic population (CD8? T cells). However,
underlying mechanisms that influence the activity of
effector CD4? T cells in the absence of CD8? T cells are
poorly defined. CD8?Foxp3? T cells were reported to
mediate immunosuppression in cancer patients [47].
Depletion of these CD8?Foxp3? Tregs in addition to
CD4?Foxp3? Tregs might allow for antitumor cytotoxic
function of CD4? T cells and tumor rejection. Moreover,
some of the molecules that are produced by CD8? T cells,
such as granzymes, may have immunomodulatory effects
on other T cells [48].
To demonstrate that the increased expression of GzmB
by effector CD4? T cells resulted in antigen-specific
cytotoxicity in vivo after depletion of Foxp3? Tregs, we
performed an in vivo CTL assay. CD4? T cells showed
potent killing activity of peptide-loaded targets in the drLN
of FBL-3-bearing mice. The acquisition of cytotoxic
activity by tumor-reactive CD4? T cells is particularly
striking since it only emerged when the suppressive func-
tion of Tregs was blocked. From previous work, we knew
that CD4? T cells can help rejection of tumors through
indirect effects on NK cells [49] and tumor-infiltrating
macrophages [1, 50, 51] and Tregs can negatively influence
this help by inhibiting IFN-c synthesis [52]. Cytotoxic
CD4? targeting viral antigens [53–55] and alloantigens
[56–58] have been described previously, but in these
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models, the influence of Tregs on effector CD4? T-cell
activity was not investigated but the tumor or the pathogen
was eliminated by adoptive transfer of effector CD4? T
cells [57, 59]. Quezada et al. [57] showed effector CD4?
T-cell-dependent tumor rejection when radiotherapy and
adoptive transfer of tumor-reactive CD4? T cells were
combined with the blockade of the CTLA-4 molecule that
is expressed on Tregs [60, 61], suggesting that Tregs
influenced cytotoxic CD4? T cells in this model as well.
As published previously, CD4? T cells cannot directly
recognize FBL-3, since they only express MHC class I but
not MHC class II molecules in vitro [27] (Supplementary
figure S3a,). However, our in vivo experiments strongly
suggest cytotoxic activity of CD4? T cells against FBL-3
tumor cells. In the current study (Supplementary figure
S3b), we showed that after being in the host environment, a
proportion of the inoculated MHC II-deficient FBL-3 cells
became I-Ab-positive. In addition, CD4? T cells can sup-
port killing of tumor cells by indirect mechanisms including
recruitment of antigen-presenting cells [27, 62] or killing
stroma cells [63] that support tumor growth. A combination of
such mechanisms can elucidate the antigen-specific elimina-
tion of FBL-3 tumors by cytotoxic CD4? T cells.
It is well established that solid tumors are often infil-
trated by macrophages. As previously published, these cells
play an important role in the FBL-3 tumor model [27]. In
our study, we illustrate significant expansion of activated
CD11b?F4/80? macrophages that produce TRAIL in
drLNs after depletion of Tregs and CD8? T cells. More-
over, infiltration of CD11b? cells into the tumor mass was
shown, which suggests an antitumor effector function of
macrophages. Activated macrophages have been reported
to secrete a number of molecules with tumorocidal effects,
like nitric oxide and reactive oxygen intermediates, and
thus can partly mediate antitumor activity [64]. In addition,
antitumor function of macrophages can be stimulated by
IFN-c-producing CD4? T cells. However, macrophages
alone could not control FBL-3 cell growth in the absence of
CD4? and CD8? T cells (Fig. 4g). Thus, we believe that
tumor-specific CD4? T cells can facilitate direct anti-tumor
activity, which can be supported by TRAIL? macrophages
inducing the classical macrophage activation pathway that
contributes to inhibition of tumor cell growth [65].
The direct antitumor role of CD4? T cells has been
controversially discussed since most tumors do not express
MHC II and thus cannot be directly recognized by CD4? T
cells. Nonetheless, there are a number of HLA-DR-
expressing tumors in patients [66]. Moreover, HLA-DR
expression is associated with better prognosis in colorectal
cancers [67]. The ability of MHC II-negative tumors to
start to express class II molecules in the tumor microen-
vironment can be applied in cancer immunotherapy.
Recent investigations in melanoma patients showed
effectiveness of adoptive CD4? T-cell therapy [68]. Thus,
analyzing for HLA-DR expression of the primary tumor
and metastasis and subsequent adoptive CD4? T-cell
transfer might be a promising approach for future
immunotherapy.
Cytotoxic CD4? T-cell activity against MHC II-nega-
tive tumors can also be used in cancer immunotherapy.
Genetic modification of cytotoxic T cells with chimeric
antigen receptors (CARs) specific for tumor antigen allows
MHC-independent antigen recognition that nonetheless
retains the T-cell effector mechanisms that are needed to
eliminate tumor cells [69].
In conclusion, our studies have established a critical role
for cytotoxic CD4? T cells in the context of oncoviral
diseases. We propose that effector CD4? T cells, which are
largely regulated by Foxp3? Tregs during tumor formation,
are capable of maintaining immune control against FBL-3
tumor via direct killing and can functionally replace CD8?
T cells. We suggest that cytotoxic CD4? T-cell immune
responses may be induced therapeutically to enhance
resistance against oncovirus-associated tumors.
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